Prediction Of Clinical Radiosensitivity Caused By Ionising Radiation During Radiotherapy.
Funder
National Health and Medical Research Council
Funding Amount
$447,750.00
Summary
Around one to five percent of cancer patients suffer from significant side effects in normal tissue exposed to ionizing radiation during radiotherapy. Although radiotherapy is an effective therapy for cancer treatment, the amount of radiation is generally restricted to minimize the incidence of these severe side effects (radiosensitivity). This means that individuals who don't have radiosensitivity are not getting the dose of radiation that would be most beneficial. A major goal of radiation bio ....Around one to five percent of cancer patients suffer from significant side effects in normal tissue exposed to ionizing radiation during radiotherapy. Although radiotherapy is an effective therapy for cancer treatment, the amount of radiation is generally restricted to minimize the incidence of these severe side effects (radiosensitivity). This means that individuals who don't have radiosensitivity are not getting the dose of radiation that would be most beneficial. A major goal of radiation biology research is to develop efficient predictive measures that could identify radiosensitive individuals prior to treatment. This predictive ability would enable the individualisation of radiotherapy radiation doses, which should result in improvement of tumour control rates and a reduction in the incidence of side effects associated with radiotherapy. We aim to understand radiosensitivity at the molecular level using the powerful technology of microarrays. Using microarray technology, thousands of genes can be tested for expression activity simultaneously. We have a unique tissue bank established from many radiosensitive and non-sensitive control radiotherapy patients. The use of microarray technology on samples from this unique tissue bank may enable the gene expression pattern of individuals that display radiosensitivity to be distinguished from the rest of the population. In conjunction, two additional tests will be used to determine who is susceptible to radiosensitive reactions which include assessment of a DNA repair pathway and assessment of the length of the telomeres (Caps on the ends of the chromosomes), both of which have been shown to be involved with radiosensitivy. This experimentation will hopefully lead to the development of a predictive assay for use in the clinic for cancer patients prior to receiving radiotherapy.Read moreRead less
Pesonalised Risk Prediction For Severe Treatment-related Gastrointestinal Toxicity In Paediatric Cancer Patients Using Pre-treatment Gut Microbiome Analysis
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
The gut is home to trillions of good and bad bacteria, critical to human health. Each person has a different balance of bacteria, unique to their gut, which shapes their immune system and susceptibility to disease. I will investigate how the unique gut bacteria, in children with blood cancer, can be used to predict which children will develop severe gut side effects (diarrhoea) from their chemotherapy. This will identify high-risk children, enable personalised treatment and improve survival.
Identification And Molecular Characterisation Of High-risk Premalignant Breast Lesions
Funder
National Health and Medical Research Council
Funding Amount
$560,382.00
Summary
Understanding the full repertoire of genetic events that underlie the development of breast cancer may allow development of prevention strategies. This study will analyse genetic data of benign breast lesions that may be non-obligate precursors of breast cancer. Importantly, clinical management of these lesions is difficult. A reliable method of predicting the risk of progression to cancer would be a significant advance, with benefits to individual patients and also the health system.
Personalising Care In Operable Pancreas Cancer. GAP-T: A Study Of Imaging And Molecular Biomarkers To Guide Treatment Of Patients Receiving Preoperative Chemotherapy Followed By Surgery.
Funder
National Health and Medical Research Council
Funding Amount
$405,345.00
Summary
We are studying ways to improve how we treat patients with pancreatic cancer. We will use a novel imaging tool, the PET scanner, to show where active cancer is and how quickly and how well a new drug combination (gemcitabine and nab-paclitaxel) is affecting the cancer. We will also study if measuring the expression of specific proteins (SPARC and hENT1) in the cancer affects the outcome and will allow us to determine ahead of time which patients will benefit most from the drugs.
Development Of A Sensitive Point Of Care Diagnostic Assay For Troponin I
Funder
National Health and Medical Research Council
Funding Amount
$137,650.00
Summary
This research aims to develop a diagnostic for immediate monitoring of patients presenting with chest pain, with the presumption of heart attack. The novel diagnostic platform will enable the estimation of a key indicator of heart muscle damage to be performed within a ten to fifteen minute window. This will aid speedier diagnosis and propoer triage of patients presenting with chest pain.
Assessment And Prediction Of Blood Flow Dynamics In Congenital Aortic Abnormalities Using Image-based Computer Modelling And Wave Intensity Analysis
Funder
National Health and Medical Research Council
Funding Amount
$390,925.00
Summary
Severe aortic abnormality is a serious problem in many infants with congenital heart disease, but it is often unclear what type of treatment will optimise blood flow and minimise the risk of later complications. This study aims to harness recent developments in blood flow modelling, magnetic resonance imaging and advanced blood flow analysis techniques to determine the factors that lead to complications in these children, thereby providing crucial information for improving treatment strategies.
Biomarkers In Barrett's Oesophagus And Oesophageal Adenocarcinoma
Funder
National Health and Medical Research Council
Funding Amount
$67,690.00
Summary
Barrett’s oesophagus (BO) is a condition in which the normal lining of the lower oesophagus is replaced with intestine-like tissue as a response to long-standing acid reflux. BO can progress to oesophageal adenocarcinoma (OAC), an aggressive cancer with poor 5-year survival rates of ~15%. This project aims at detecting genetic and molecular changes that occur in both BO and OAC and which may help predict the risk of progression as well as survival for patients affected by this disease entity.
Forecasting The Impact Of Climate Change On Dengue Transmission
Funder
National Health and Medical Research Council
Funding Amount
$506,432.00
Summary
Dengue fever (DF) is the most important mosquito-transmitted viral disease in the world. The large-scale re-emergence of DF in the Asia-Pacific region during the past few decades has renewed its status as a serious international public health problem. Global climate change is anticipated to impact upon the biology and ecology of vectors and consequently the risk of DF transmission. The principal research aim of this study is to project the impact of future climate change on DF.